Cordiant may opt for Zenith poison pill
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Cordiant, the advertising group which announced a three-way split of its operations on Monday, has admitted it might place pre-emption rights over shares in its Zenith Media Worldwide subsidiary.
Bob Seelert, Cordiant's chief executive, said no decision had been taken about pre-emption rights which could be used as a "poison pill" defence against predators.
Cordiant's position on the issue would be outlined in the demerger prospectus which would be launched ahead of a special shareholder meeting in October, said Mr Seelert.
The company is looking for a partner for Zenith. However, if no partner is found then, under current proposals, Zenith will be owned equally by Cordiant's other two businesses that are being demerged - the Saatchi & Saatchi advertising agency and the Bates marketing group.
Zenith has offices in 22 countries but is considered too small to compete in the media buying sector, a business that entails an agency buying advertising space for clients.
Regardless of any poison pill, some industry experts question how attractive Zenith would be to a buyer. One said: "Zenith is interesting because of the accounts it holds. But what would stop those accounts moving back to its former parent company in the event of a takeover?"
The Cordiant demerger, which could formally take effect in December with the stock listing of Saatchi & Saatchi and Bates in both London and New York, has put all three groupings into play as potential takeover targets.
One rival media services group said it would certainly take a look at the individual businesses. A senior executive said: "Everyone in the industry will be putting the [acquisition] slide rule over all these new companies."
Lorna Tilbian, media analyst with Panmure Gordon, said: "Both [Saatchi and Bates] could go in takeovers. It seems likely that a partner will be brought in to Zenith so it can be floated off."
But speculation about Saatchi & Saatchi and Bates as takeover targets was brushed aside by Mr Seelert. He said: "Frankly we do not see it that way. Both are robust companies that are perfectly capable of standing on their own."
Young & Rubicam, one of the US advertising groups linked by analysts as a possible future partner for Zenith, ruled itself out of the running yesterday.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments